

Application No.: 09/623,543

2

Docket No.: 500862002200

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Claims 1-21 (Canceled).**BEST AVAILABLE COPY**

Claim 22 (Allowed): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide wherein said kringle 5 peptide comprises SEQ ID NO: 8 and a reactive group coupled thereto, said reactive group reacting with an amino group, a hydroxyl group, or a thiol group on a blood component to form a stable covalent bond, wherein said reactive group is a succinimidyl-containing group or a maleimido-containing group.

Claim 23 (Canceled).

Claim 24 (Allowed): The method of claim 22, wherein said blood component is a blood protein.

Claim 25 (Allowed): The method of claim 22, wherein said modified peptide is reactive with a thiol group on a blood protein.

Claims 26-27 (Canceled).

Claim 28 (Allowed): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide comprising a kringle 5 peptide with a maleimido group coupled thereto, said maleimido group reacting with a thiol group on human serum albumin to form a stable covalent bond wherein said kringle 5 peptide comprises SEQ ID NO: 8.

Claim 29-32 (Canceled).

sf-2142179

Application No.: 09/623,543

3

Docket No.: 500862002200

Claim 33 (Allowed): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide of the sequence (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂ (SEQ ID NO: 39).

BEST AVAILABLE COPY

Claim 34 (Previously Presented): A method of using a modified kringle 5 peptide wherein said kringle 5 peptide comprises SEQ ID NO: 8 and a maleimido group coupled to said kringle 5 peptide wherein said maleimido group reacts with a thiol group on a blood protein to form a covalent bond, for manufacturing an anti-angiogenic medicament.

Claim 35 (Currently Amended): A conjugate comprising a modified kringle 5 peptide covalently bonded to a blood component, where said modified kringle 5 peptide comprises SEQ ID NO: 8 and a reactive group coupled thereto ~~wherein said reactive group reacts with an amino group, a hydroxyl group, or a thiol group on said blood component to form a stable covalent bond, and~~ wherein said reactive group is a succinimidyl-containing or a maleimido-containing group, and wherein said reactive group is covalently bonded to a thiol group on the blood component.

Claim 36 (Previously Presented): The conjugate of claim 35, wherein said blood component is a blood protein.

Claim 37 (Canceled).

Claim 38 (Currently Amended): The conjugate of claim 36, wherein said reactive group is covalently bonded to ~~[[a]]~~ the thiol group on said blood protein.

Claims 39-41 (Canceled).

Claim 42 (Previously Presented): A composition for providing an anti-angiogenic effect to a patient, comprising a conjugate of claim 35 in association with a pharmaceutically acceptable carrier.

sf-2142179

Application No.: 09/623,543

4

Docket No.: 500862002200

Claim 43 (Previously Presented): The composition of claim 42, wherein said blood component is a blood protein.

Claim 44 (Canceled).

BEST AVAILABLE COPY

Claim 45 (Currently Amended): The composition of claim 42, wherein said reactive group is covalently bonded to [[a]] the thiol group on said blood protein.

Claim 46-48 (Canceled).

Claim 49 (Currently Amended): A conjugate comprising a modified kringle 5 peptide covalently bonded to albumin, where said modified kringle 5 peptide comprises SEQ ID NO: 8 and a reactive group coupled thereto, ~~wherein said reactive group reacts with an amino group, a hydroxyl group or a thiol group on albumin to form stable covalent bond, and wherein said reactive group is a succinimidyl-containing and maleimido-containing group~~ covalently bonded to a thiol group on the albumin.

Claim 50 (Previously presented): The method of claim 22 wherein said reactive group is a succinimidyl-containing group.

Claim 51 (Previously presented): The method of claim 22 wherein said reactive group is a maleimido-containing group.

Claim 52 (Previously presented): The conjugate of claim 35 wherein said reactive group is a succinimidyl-containing group.

Claim 53 (Previously presented): The conjugate of claim 35 wherein said reactive group is a maleimido-containing group.

sf-2142179

Application No.: 09/623,543

5

Docket No.: 500862002200

BEST AVAILABLE COPY

Claim 54-55 (Canceled).

Claim 56 (New): A composition comprising the conjugate of claim 49 in association with a pharmaceutically acceptable carrier.

sf-2142179